Outcomes of this secondary analysis
AKI, Death
SECONDARY
The primary outcome for this secondary analysis was to evaluate the impact of protein dose on TTDA among patients with AKI. Death was a competing risk and patients who died within 60 days of ICU admission were considered to have never been discharged alive regardless of prior hospital discharge. Secondary outcomes included 60-day mortality, duration of KRT from randomization, and incidence of KRT post randomization. In addition, we also compared the urea levels between groups during the first 12 study days. Clinical outcomes were assessed up to a maximum of 60 days post randomization while the patient was in the hospital. Protein and energy delivery were assessed for the first 28- and 12-days post randomization, respectively.